Earnings Call · Q2 FY2021·2021-08-03

Q2 21EPS +30.43%·Rev n/aQ1 21EPS +100.00%*·Rev n/aQ4 20EPS 0.00%·Rev n/aQ3 20EPS +34.43%·Rev n/a⚠ consensus missing

RIGEL PHARMACEUTICALS INC RIGL

Dolly Vance — Investor Relations

Raul Rodriguez — Chief Executive Officer

Dave Santos — Chief Commercial Officer

Wolfgang Dummer — Chief Medical Officer

Dean Schorno — Chief Financial Officer

−1.3%1d on move date−0.8% vs SPY3d+0.8%5d+3.2%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RIGL calls or request research access.

More RIGL calls Browse calls Request research access